326 related articles for article (PubMed ID: 10982016)
1. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
[TBL] [Abstract][Full Text] [Related]
2. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
4. Hybrid thyroid carcinoma with a coarse chromatin pattern and nuclear features of papillary thyroid carcinoma.
Mai KT; Bokhary R; Yazdi HM; Thomas J
Pathol Res Pract; 2002; 198(4):253-60. PubMed ID: 12049333
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
7. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
9. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules.
van Hoeven KH; Kovatich AJ; Miettinen M
Diagn Cytopathol; 1998 Feb; 18(2):93-7. PubMed ID: 9484636
[TBL] [Abstract][Full Text] [Related]
11. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
12. Ret oncogene protein expression in papillary thyroid carcinoma and related lesions.
Mai KT; Landry DC; Thomas J; Yazdi HM; Perkins DG; Odell PF
Tumori; 2001; 87(3):166-72. PubMed ID: 11504372
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
14. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
15. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
16. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.
Miettinen M; Kärkkäinen P
Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756
[TBL] [Abstract][Full Text] [Related]
17. Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1.
Nehal S; Mittal R; Misra P; Rath J; Senapati U
Ann Diagn Pathol; 2022 Jun; 58():151931. PubMed ID: 35255428
[TBL] [Abstract][Full Text] [Related]
18. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
19. Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease?
Anderson SR; Mandel S; LiVolsi VA; Gupta PK; Baloch ZW
Diagn Cytopathol; 2004 Jul; 31(1):64-7. PubMed ID: 15236269
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]